Answers are grounded in this paper and cite their sources.
Randomized trial compares azathioprine and betamethasone therapies for hair regrowth in alopecia areata, indicating superior outcomes with azathioprine.
Alopecia Areata (AA) is a disease that leads to unpredictable hair loss. Objective: To assess and compare the efficacy of Weekly Azathioprine Pulse (WAP) versus Betamethasone Oral Mini-Pulse (BOMP) therapy in Alopecia areata. Methods: Sixty patients with ≥15% scalp involvement were divided into two groups. The WAP group given azathioprine (300 mg) once weekly; the BOMP group received betamethasone (5 mg) on two consecutive days weekly. A randomized controlled trial was performed at the Dermatology Department of Sheikh Zayed Hospital, Rahim Yar Khan, over a 6-month (March–September 2023). Both treatments continued for 12 weeks. At baseline, 12 weeks, and 12 weeks post-treatment SALT scores were recorded. Efficacy was defined as ≥75% hair regrowth. Results: The male-to-female ratio was 1.9:1 with 39 (65%) males and 21 (35%) females. WAP group baseline SALT score of 42.60 ± 13.75 decreased to 13.97 ± 11.79 after a follow-up period of 12 weeks post-treatment, compared to BOMP group reduction from 38.67 ± 10.76 to 21.63 ± 10.96; regrowth percentage was higher in WAP (68.62%) vs. BOMP (44.28%), p=0.001. In the WAP group, 13 (43.3%) of patients achieved efficacy with ≥76% hair regrowth, compared to 3 (10%) in the BOMP group, showcasing a significant disparity (p-value=0.009). Relapse at three months occurred in 1 (3.3%) participant in the WAP group and 2 (6.7%) participants in the BOMP group (p-value of 0.500). Conclusion: This study demonstrated that WAP therapy was superior to BOMP in moderate to severe AA with notable hair regrowth.
No takes yet. Share an insight, caveat, or question.
Usman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: